Vidac Pharma Holding Plc's Approach Bolstered by New Study

A recent study confirms Vidac Pharma's innovative strategy in cancer treatment. Vidac Pharma Holding Plc continues to receive support for its approach of mitochondrial transplantation as a way to improve tumor cell response to chemotherapy. This innovation is noted for reducing adverse effects of cancer treatment.

The study highlights mitochondria's role in tumor biology, suggesting new possibilities for combination therapies. Vidac Pharma's method focuses on interrupting the Warburg Effect, a unique cancer metabolism process, by blocking hexokinase 2 binding in mitochondria. Clinical studies show this improves immune response within tumors.

Utilizing a multi-stage discounted cash flow model, Vidac's pipeline drugs for actinic keratosis and cutaneous T-cell lymphoma are valued individually. The company maintains a target stock price of EUR 4.30, with a "Buy" recommendation.